Image

    Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel

    August 2023 in “ Drug safety ”
    Joanne Chiu, Soo Chin Lee, J. C. Ho … Rebecca Dent
    Studysummary This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Optimizing Treatment Management of Trastuzumab Deruxtecan in Clinical Practice of Breast Cancer ESMO Open · 2022
    2. Psychological Aspects of Hair Disorders: Considerations for Dermatologists, Cosmetologists, Aesthetic, and Plastic Surgeons Skin appendage disorders · 2021